Cheap pill used to treat HIV could cure Alzheimer’s disease: study

By Mark Waghorn via SWNS

A £7 ($8.74 USD) pill used to treat HIV could cure Alzheimer's, according to new research.

It clears rogue proteins in the brain - preventing dangerous build-up and slowing progression of the disease.

The results are encouraging as Maraviroc - sold under the brand name Selzentry - is already prescribed to patients with the Aids virus.

It is hoped repurposing the medication will reverse memory loss in older people.

Senior author, Professor David Rubinsztein of the UK Dementia Research Institute at Cambridge University, said: "We're very excited about these findings.

"We've not just found a new mechanism of how our microglia hasten neurodegeneration, we've also shown this can be interrupted, potentially even with an existing, safe treatment."

The brain and central nervous system have their own specialist immune cells, known as microglia, which should protect against unwanted and toxic materials.

In dementia, they kick into action, but in such a way as to impair the process of autophagy - a process by which cells degrade and recycle their components.

In lab rodents, the team showed during neurodegeneration microglia release a suite of molecules which in turn trigger a genetic switch, known as CCR5.

It leads to a chemical called tau gathering in clumps, destroying brain cells.

Prof. Rubinsztein said: "The microglia begin releasing these chemicals long before any physical signs of the disease are apparent.

"This suggests - much as we expected - that if we're going to find effective treatments for diseases such as Huntington's and dementia, these treatments will need to begin before an individual begins showing symptoms."

The team tested mice that had been genetically-altered to develop forms of dementia characterized by the build-up of tau.

When the action of CCR5 was knocked out, the animals were protected - unlike controls.

The gene is also used by HIV as a 'doorway' into our cells. It is inhibited by maraviroc - which stops the virus making more copies of itself.

About 90 per cent of patients have the strain the drug can suppress.

The team administered the drug for four weeks when the mice were two months old.

When the researchers looked at the animals' brains, they found a significant reduction in the number of toxic proteins when compared to untreated peers.

The same effect was observed in mice with dementia and Huntington's - a cognitive disorder that leads to it.

The drug reduced tau aggregates compared to untreated mice, but it also slowed down the loss of brain cells.

The treated mice performed better at an object recognition test, suggesting that the drug slowed down memory loss, reports the journal Neuron.

Professor Rubinsztein added: "Maraviroc may not itself turn out to be the magic bullet, but it shows a possible way forward.

"During the development of this drug as a HIV treatment, there were a number of other candidates that failed along the way because they were not effective against HIV.

"We may find that one of these works effectively in humans to prevent neurodegenerative diseases."

The number of dementia cases worldwide will triple to more than 150 million by 2050. New treatments are desperately needed.